bladder cancer
Conditions
Interventions
test group:Take 2g of krill oil orally every day, krill oil food specifications: 1g/capsule, 1 capsule within 30 minutes after breakfast and dinner
control group:Oral placebo capsules, the contents of which are olive oil, food specifications: 1g/capsule, 1 capsule within 30 minutes after breakfast and dinner
Sponsors
Qilu Hospital of Shandong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Diagnosed bladder cancer: The patient needs to be diagnosed with bladder cancer through pathological examination and have undergone bladder cancer surgery. 2.Planned to receive bladder infusion therapy: Patients need to plan to receive bladder infusion therapy after surgery and agree to participate in the study. 3.Age range: 18 to 75 years old. 4.Normal blood, liver and kidney function: Laboratory tests showed that the patient's blood routine, liver function and kidney function were within the normal range. 5.Signed informed consent: The patient understands the content of the study and voluntarily signs the informed consent.
Exclusion criteria
Exclusion criteria: 1.Serious comorbidities: including but not limited to heart disease, severe liver and kidney insufficiency, uncontrolled hypertension, diabetes, etc. 2.History of allergies: Patients with a known history of allergy to krill oil or perfusion drug components. 3.History of prior chemotherapy: Patients who have received perfusion therapy prior to this study; 4.History of other malignant tumors: Patients with a history of other malignant tumors. 5.Pregnancy or lactation: Female patients who are pregnant or lactating. 6.Psychiatric illness: Patients with a history of severe psychiatric illness or currently receiving treatment for psychiatric illness. 7.Poor study compliance: Patients who believe that they are unable to complete the entire trial process as required by the study; 8.Other: Other conditions that the investigator considers unsuitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The degree to which bladder irritation has been relieved;Incidence of hematuria, urinary tract infections and systemic adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life scores; | — |
Countries
China
Contacts
Public ContactWeiqiang Jing
Qilu Hospital of Shandong University
Outcome results
None listed